Status:
COMPLETED
A Device Study in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate the safety and tolerability of two different devices that may be used to inject medication just under the skin. Participants will receive placebo; no acti...
Eligibility Criteria
Inclusion
- Overtly healthy male or female participants as determined by medical history, laboratory tests, physical examination, 12-lead ECGs, and vital signs.
- Body mass index (BMI) within the range of 18 to 32 kilograms per meter squared (kg/m²)
- Female participants must not be pregnant, and must test negative for pregnancy
- Agree to video recording during each administration event using the autoinjector or bolus injector
Exclusion
- Have known allergies to any components of the placebo or related compounds, or history of significant atopy, or known allergies or irritation to adhesives (e.g. skin adhesives, band aid)
- Have an abnormal blood pressure as determined by the investigator
- Have a history or presence of a bleeding disorder
- Have a history of any types of neuropathy, radiculopathy, or fibromyalgia that would affect perception in abdominal wall
- Have self-perceived dullness or loss-of-sensation on either side of the body or the abdomen
- Have any condition that could affect pain perception from an injection
- Have tattoos or scars over the abdomen, or other factors (eg, rash, excessive folds of skin) that, in the investigator's opinion, would interfere with injection-site assessments
- Have an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the trial
- Are currently using or intend to use painkillers, aspirin, or other nonsteroidal Anti-inflammatory drugs, anticoagulant or antiaggregant drugs, over-the-counter or prescription medication for pain or inflammation
- Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 2 months or 5 half-lives (whichever is longer) should have passed
- Are unwilling to stop alcohol consumption
- Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
- Are unwilling to abide by the tobacco restrictions
- Poor peripheral venous access
- Have a pacemaker and/or similar devices/other implantables
Key Trial Info
Start Date :
September 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 22 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04848402
Start Date
September 27 2021
End Date
July 22 2022
Last Update
March 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LABCORP
Leeds, United Kingdom, LS2 9LH